{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:26:12Z","timestamp":1782365172602,"version":"3.54.5"},"reference-count":34,"publisher":"Impact Journals, LLC","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,6,11]]},"DOI":"10.18632\/oncotarget.26982","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T18:22:51Z","timestamp":1560277371000},"page":"3835-3839","source":"Crossref","is-referenced-by-count":10,"title":["Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium"],"prefix":"10.18632","volume":"10","author":[{"given":"Jingming","family":"Wang","sequence":"first","affiliation":[{"name":"Immunogenomics Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Linxweiler","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Immunogenomics Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[{"name":"Immunogenomics Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc G.T.","family":"Morris","sequence":"additional","affiliation":[{"name":"Immunogenomics Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"1","unstructured":"U.S. Food and Drug Administration. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. 2017. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm560167.htm."},{"key":"2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11912-019-0761-y","article-title":"TRK Inhibitors: Clinical Development of Larotrectinib","volume":"21","author":"Sigal","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","author":"Pazdur","year":"2019","journal-title":"Clin Cancer Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jnci\/djy060","article-title":"Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas","volume":"110","author":"Morris","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Nature"},{"key":"6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrc1190","article-title":"Tobacco carcinogens, their biomarkers and tobacco-induced cancer","volume":"3","author":"Hecht","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Stratton","year":"2016","journal-title":"Science"},{"key":"8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.18632\/oncotarget.13613","article-title":"Impacts of cigarette smoking on immune responsiveness: up and down or upside down?","volume":"8","author":"Dai","year":"2017","journal-title":"Oncotarget"},{"key":"9","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1513\/AnnalsATS.201306-154MG","article-title":"Cigarette smoke effects on innate immune mechanisms in the nasal mucosa. Potential effects on the microbiome","volume":"11","author":"Jaspers","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nri803","article-title":"Effects of cigarette smoke on the immune system","volume":"2","author":"Sopori","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Moreira","year":"2015","journal-title":"Science"},{"key":"12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Kivork","year":"2014","journal-title":"Nature"},{"key":"13","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Kannan","year":"2014","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Motzer","year":"2019","journal-title":"Nat Genet"},{"key":"15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12967-019-1773-y","article-title":"Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer","volume":"17","author":"Ohira","year":"2019","journal-title":"J Transl Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Allison","year":"2018","journal-title":"Cancer Discov"},{"key":"17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Felip","year":"2015","journal-title":"N Engl J Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Iglesias Docampo","year":"2016","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Leming","year":"2015","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Wagstaff","year":"2015","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial","volume":"33","author":"Lambert","year":"2015","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Kronenberg","year":"2013","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"10143","DOI":"10.1073\/pnas.0401422101","article-title":"Effects of cigarette smoke on the human airway epithelial cell transcriptome","volume":"101","author":"Brody","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Gajewski","year":"2017","journal-title":"Cell"},{"key":"26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Alizadeh","year":"2015","journal-title":"Nat Methods"},{"key":"27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Hacohen","year":"2015","journal-title":"Cell"},{"key":"28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"Manley","year":"2016","journal-title":"Genome Biol"},{"key":"29","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Seshan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells with CIBERSORT","volume":"1711","author":"Alizadeh","year":"2018","journal-title":"Methods Mol Biol"},{"key":"31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/carcin\/bgz003","article-title":"XPC protects against smoking- and carcinogen-induced lungadenocarcinoma","volume":"40","author":"Sears","year":"2019","journal-title":"Carcinogenesis"},{"key":"32","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1093\/carcin\/bgm122","article-title":"Potent carcinogenicity of cigarette smoke in mice exposed early in life","volume":"28","author":"De Flora","year":"2007","journal-title":"Carcinogenesis"},{"key":"33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"Gajewski","year":"2015","journal-title":"Trends Immunol"},{"key":"34","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/0008-5472.CAN-18-2864","article-title":"Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma","volume":"79","author":"Hogan","year":"2019","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T11:48:22Z","timestamp":1588852102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":34,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,6,11]]}},"alternative-id":["26982","31231463"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26982","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]}}}